FDA Proposes Antihypertensive Class Indication For Reducing CV Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Adding an indication for reducing cardiovascular adverse event risk is one option FDA will have its Cardiovascular & Renal Drugs Advisory Committee consider for antihypertensive class labeling June 15. Other class labeling options offered in FDA briefing document would amend the clinical trials section.